Summary
Introduction
KV Pharmaceutical is a fully integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The company received the FDA approval for Evamist in July 2007 for the treatment of moderate to severe vasomotor symptoms due to menopause.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
KV Pharmaceutical's product portfolio includes branded products that are marketed by its wholly owned subsidiary, Ther-Rx; and generic products which are marketed by ETHEX, its generic products marketing subsidiary. KV Pharmaceutical derives majority of its revenues from product sales of technologically distinguished generic drugs marketed through its subsidiary ETHEX, branded pharmaceuticals through its subsidiary Ther-Rx and value-added raw materials, including microencapsulated products through Particle Dynamics subsidiary. KV Pharmaceutical's major contributor to sales growth out to 2010 will be the sales of generic products marketed by its wholly owned subsidiary, ETHEX. ETHEX sales are expected to increase from $204 million to $389 million between 2006 and 2010.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
|
